N-Acetylcysteine in Heart Failure With Coexistent Chronic Renal Failure

Status Recruiting

Clinical Trial Summary

Treatment with n-acetylcysteine in patients with heart failure and chronic renal failure leads to improvements in vascular function and in renal function.

Clinical Trial Description

Ten patients will be invited to participate in the trial. After obtaining informed consent, the ten patients will be randomly assigned to one month of treatment with oral n-acetylcysteine 500mg or placebo twice daily for thirty days in addition to their regular therapy. At enrolment the patients will be educated and counselled about the trial and the intervention medication. Patients will also have a blood test (serum creatinine) that will allow the calculation of their renal function by use of the Cockroft Gault equation. Blood samples will also be frozen and stored. Patients will also undergo an ultrasound test of the function of their arm blood vessels. Both the blood test and the ultrasound test will be repeated at the completion of the thirty day trial period. Again the blood test sample will be frozen and stored. Subjects will then cross over to the other treatment arm for a further one month period, with the same testing at the end. ;

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00532688
Study type	Interventional
Source	Bayside Health
Contact	David Kaye, PhD FRACP
Phone	610390762000
Email	david.kaye@baker.edu.au
Status	Recruiting
Phase	Phase 2/Phase 3
Start date	September 2007
Completion date	February 2008

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03246984` - VALUE- Vascular Access Laminate eUropean Experience. A Post Market Surveillance Study to Assess the Safety and Effectiveness of VasQ	N/A
Completed	`NCT02922361` - Spending and Outcomes for Complex Medicare Advantage Patients
Completed	`NCT02235571` - iChoose Decision Kidney Aid for End-Stage Renal Disease Patients	N/A
Completed	`NCT01930396` - Use of Tinzaparin for Anticoagulation in Hemodialysis	Phase 4
Completed	`NCT01922843` - A Phase 2 Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis	Phase 2
Completed	`NCT01933789` - Improving Communication About Serious Illness	N/A
Not yet recruiting	`NCT01674660` - Factors Associated With Interdialytic Blood Pressure Variability in Maintenance Hemodialysis Patients	N/A
Not yet recruiting	`NCT01157260` - The Effects of AST-120 on Endothelial Dysfunction in Patients With Chronic Kidney Disease	Phase 4
Completed	`NCT01209403` - Insulin-like Growth Factor (IGF-I) in Hemodialysis Patients	Phase 4
Completed	`NCT00753116` - Renal Denervation in End Stage Renal Disease Patients With Refractory Hypertension	Phase 1
Completed	`NCT00534144` - Comparison Between Effects of Two Iron Preparations on Protein in the Urine	Phase 1
Completed	`NCT00528788` - How Vitamin D Analogues Affect Endothelial Cells in Patients on Dialysis	Phase 4
Completed	`NCT00382044` - Audit of the Effect of Changing From IV to SC Administration of ESA's in Haemodialysis Patients	N/A
Completed	`NCT00226902` - Vascular Reactivity in Kidney Disease Patients	N/A
Recruiting	`NCT00235287` - Pulse Wave Velocity, Pulse Wave Morphology and Blocking of the Reninangiotensin System in Patients With Chronic Kidney Disease	Phase 4
Completed	`NCT00224081` - DRIVE Trial (Dialysis Patients' Response to Intravenous [IV] Iron With Elevated Ferritin)	Phase 4
Completed	`NCT00071214` - Study to Evaluate the Effectiveness of StaphVAX in Adults on Hemodialysis	Phase 3
Completed	`NCT00049907` - Cardiac and Renal Disease Study (CARDS)	N/A
Completed	`NCT00006297` - Risk Factors for CV Disease in a Dialysis Cohort	N/A
Completed	`NCT05718765` - The Effect of Physical ACtivity Enhancement Scheme (PACES) in Hemodialysis Patients	N/A